Roche CEO Severin Schwan (Image: Reuters/Arnd Wiegmann)
October 25, 2019 06:06 AM EDTUpdated 11:17 AM
FDA+

FTC staff signs off on Roche $4.3B deal for Spark — re­port

Natalie Grover

Reporter

Roche is one step clos­er to reg­u­la­to­ry en­dorse­ment — in the form of an FTC staff rec­om­men­da­tion — to buy Spark Ther­a­peu­tics with­out any as­set sales, ac­cord­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times